Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183582 | 1.00 | NR1H2 (0.67) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL5443139 | 0.93 | NR1H2 (0.56) | NR1H2ESR2ADORA1MAPTKDM4E | |
| SCHEMBL31054069 | 0.90 | ESR2 (0.68) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL29557668 | 0.88 | NR1H2 (0.65) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL31597683 | 0.87 | ESR2 (0.61) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL2805947 | 0.87 | ESR2 (0.61) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL4171400 | 0.86 | NR1H2 (0.65) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL17065001 | 0.86 | NR1H2 (0.65) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL4169066 | 0.86 | NR1H2 (0.65) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL31067606 | 0.86 | NR1H2 (0.65) | NR1H2ESR2ADORA1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20170145007-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145007-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | ALK, NPM1, ETV6 | NR1H2 3277/4885ESR2 2943/4885ADORA1 2866/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | NR1H2 2138/4885ESR2 3632/4885ADORA1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.